MNG486
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.522
- OXIDATIVE_PHOSPHORYLATION+0.414
- HYPOXIA+0.378
- GLYCOLYSIS+0.324
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.310
- ADIPOGENESIS+0.309
- CHOLESTEROL_HOMEOSTASIS+0.282
- P53_PATHWAY+0.269
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.245
- TNFA_SIGNALING_VIA_NFKB+0.236
Top 10 suppressed
- UV_RESPONSE_DN-0.237
- MYC_TARGETS_V1-0.232
- INTERFERON_ALPHA_RESPONSE-0.223
- SPERMATOGENESIS-0.184
- MITOTIC_SPINDLE-0.156
- INTERFERON_GAMMA_RESPONSE-0.155
- TGF_BETA_SIGNALING-0.148
- ANDROGEN_RESPONSE-0.128
- PROTEIN_SECRETION-0.081
- G2M_CHECKPOINT-0.054
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9a4f9e4a-dc97-4f8d-9075-537b62fb98d3 | — | — | 0.834 |
| 2 | d25af392-21ad-4aa6-8669-34656bf71af5 | — | — | 0.788 |
| 3 | AUR-AFEC-TTM4-A-1-1-R-A742-41 | — | C | 0.727 |
| 4 | MNG413 | — | — | 0.726 |
| 5 | MBCProject_1151_T1_RNA | — | B | 0.721 |
| 6 | SRR6013489 | — | cohortA1 | 0.717 |
| 7 | 349c48ca-ced2-42db-8a50-ea3293116623 | — | — | 0.716 |
| 8 | TCGA-AC-A5EH-01A-11R-A28M-07 | — | C | 0.714 |
| 9 | MNG278 | — | — | 0.712 |
| 10 | AUR-AERY-TTM1-A-1-1-R-A742-41 | — | C | 0.701 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.522 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.414 | Remibrutinib | — uncovered |
| HYPOXIA | 0.378 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.324 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.309 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.282 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.269 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.245 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.236 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.228 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.192 | Inavolisib | — uncovered |
| PEROXISOME | 0.176 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.172 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.169 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.169 | Inavolisib | — uncovered |
| COAGULATION | 0.165 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.161 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.153 | Inavolisib | — uncovered |
| APOPTOSIS | 0.141 | Idelalisib | — uncovered |